Does Pacific Edge have a target on its back?

Does Pacific Edge have a target on its back?
Invested capital in Cxbladder makes for an 'attractive acquisition target' (Image: supplied)
Brent Melville
Cancer diagnostic company Pacific Edge could be ripe for a takeover, analysis by investment firm Bell Potter suggests.Bell Potter, the Australian adviser to Pacific Edge’s September listing on the ASX, kicked off coverage of the Dunedin-based company with a speculative buy recommendation this week, valuing it at A$1.10 ($1.19) a share. That’s an 18% premium to Tuesday’s ASX price of 93 Australian cents, and a firm advance on its NZX Tuesday close of 99 cents. Local investment house Jarden pegs the NZX target price at $1.1...

More Markets

NZ sharemarket starts new week up 0.2%
Markets Market Close

NZ sharemarket starts new week up 0.2%

The S&P/NZX 50 Index closed at 13,499.04, up 34.58 points or 0.26%.

The Warehouse CEO Mark Stirton unveils cost reset amid margin pressure
Retail

The Warehouse CEO Mark Stirton unveils cost reset amid margin pressure

Continued margin pressure and an unsustainable cost base have led The Warehouse Group to implement a comprehensive cost reset programme, something which could see head office roles slashed to save costs.Chief executive Mark Stirton said the group’s shareholders expect decisive ac...

Banks accelerate crackdown on ‘mule’ scammers
Finance

Banks accelerate crackdown on ‘mule’ scammers

New technology picks up crooked “muleteers” more quickly.